Bevacizumab

Overview

Journal Nat Rev Drug Discov

Specialty Pharmacology

Date 2005 Jun 21

PMID 15962523

Citations 29

Authors

Lee M Ellis

Affiliations

Soon will be listed here.

Abstract

Bevacizumab (Avastin; Genentech/Roche), an antibody against vascular endothelial growth factor, was approved by the US FDA in February 2004 for the first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil-based chemotherapy. It is the first approved agent to target tumour angiogenesis.

Citing Articles

miR-493-5p Silenced by DNA Methylation Promotes Angiogenesis via Exosomes and VEGF-A-Mediated Intracellular Cross-Talk Between ESCC Cells and HUVECs.

Xiao Z, Zhao J, Ji G, Song X, Xue X, Zhang W Int J Nanomedicine. 2024; 19:7165-7183.

PMID: 39050873 PMC: 11268713. DOI: 10.2147/IJN.S464403.

The role of endothelial cell-pericyte interactions in vascularization and diseases.

Li G, Gao J, Ding P, Gao Y J Adv Res. 2024; 67():269-288.

PMID: 38246244 PMC: 11725166. DOI: 10.1016/j.jare.2024.01.016.

The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma.

Zeng H, Xu Q, Wang J, Xu X, Luo J, Zhang L Front Immunol. 2023; 14:1073133.

PMID: 36756114 PMC: 9900113. DOI: 10.3389/fimmu.2023.1073133.

Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models.

Li Y, Amaladas N, OMahony M, Manro J, Inigo I, Li Q PLoS One. 2022; 17(7):e0268244.

PMID: 35849586 PMC: 9292077. DOI: 10.1371/journal.pone.0268244.

Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.

Andrea A, Chiron A, Mallah S, Bessoles S, Sarrabayrouse G, Hacein-Bey-Abina S Front Immunol. 2022; 13:830292.

PMID: 35211124 PMC: 8861853. DOI: 10.3389/fimmu.2022.830292.